| Patent application number | Description | Published |
|---|
| 20080200446 | Substituted azetidinone compounds, processes for preparing the same, formulations and uses thereof - The present invention provides compounds represented by the structural formula (I): | 08-21-2008 |
| 20080207585 | Substituted Azetidinone Compounds, Processes for Preparing the Same, Formulations and Uses Thereof - The present invention provides compounds represented by the structural formula (I): | 08-28-2008 |
| 20080234248 | Substituted Azetidinone Compounds, Processes for Preparing the Same, Formulations and Uses Thereof - The present invention provides compounds represented by the structural formula (I): | 09-25-2008 |
| 20080312218 | FUSED TETRACYCLIC MGLUR1 ANTAGONISTS AS THERAPEUTIC AGENTS - In its many embodiments, the present invention provides tetracyclic compounds of formula I or formula II (wherein the various moieties are as defined herein) useful as metabotropic glutamate receptor (mGluR) antagonists, particularly as selective metabotropic glutamate receptor 1 antagonists, pharmaceutical compositions containing the compounds, and methods of treatment using the compounds and compositions to treat diseases associated with metabotropic glutamate receptor (e.g., mGluR1) such as, for example, pain, migraine, anxiety, urinary incontinence and neurodegenerative diseases such Alzheimers disease. | 12-18-2008 |
| 20090082336 | mGluR1 Antagonists as Therapeutic Agents - In its many embodiments, the present invention provides tricyclic compounds of formula I (wherein J | 03-26-2009 |
| 20090137575 | Fused Tetracyclic mGluR1 Antagonists as Therapeutic Agents - In its many embodiments, the present invention provides tetracyclic compounds of formula I or formula II (wherein the various moieties are as defined herein) useful as metabotropic glutamate receptor (mGluR) antagonists, particularly as selective metabotropic glutamate receptor 1 antagonists, pharmaceutical compositions containing the compounds, and methods of treatment using the compounds and compositions to treat diseases associated with metabotropic glutamate receptor (e.g., mGluR1) such as, for example, pain, migraine, anxiety, urinary incontinence and neurodegenerative diseases such Alzheimer's disease. | 05-28-2009 |
| 20090192178 | mGluR1 ANTAGONISTS AS THERAPEUTIC AGENTS - In its many embodiments, the present invention provides tricyclic compounds of formula I (wherein J | 07-30-2009 |
| 20100298381 | GAMMA SECRETASE MODULATORS - In its many embodiments, the present invention provides a novel class of 5-membered, nitrogen-containing heterocyclic compounds as modulators of gamma secretase, methods of preparing such compounds, pharmaceutical compositions containing one or more such compounds, methods of preparing pharmaceutical formulations comprising one or more such compounds, and methods of treatment, prevention, inhibition, or amelioration of one or more diseases associated with the central nervous system using such compounds or pharmaceutical compositions. | 11-25-2010 |
| 20110009392 | GAMMA SECRETASE MODULATORS - In its many embodiments, the present invention provides a novel class of heterocyclic compounds as modulators of gamma secretase, methods of preparing such compounds, pharmaceutical compositions containing one or more such compounds, methods of preparing pharmaceutical formulations comprising one or more such compounds, and methods of treatment, prevention, inhibition, or amelioration of one or more diseases associated with the central nervous system using such compounds or pharmaceutical compositions. | 01-13-2011 |
| 20110110948 | BENZENESULFONYL-CHROMANE, THIOCHROMANE, TETRAHYDRONAPHTHALENE AND RELATED GAMMA SECRETASE INHIBITORS - Disclosed are novel gamma secretase inhibitors of the formula (I): or a pharmaceutically acceptable salt, solvate, or ester thereof, wherein L | 05-12-2011 |
